RWE, Market Access, Pricing & Reimbursement Global Congress 2022 Europe

Agenda at a Glance

Day 2 - Congress

Day 2: Wednesday 2nd March 2022

CHALLENGES & OPPORTUNITIES

  • Advantages of market access teams in payer relationship
  • Payer evidence requirement in early development
  • Best practices to obtain better pricing and reimbursement
  • Strategies to improve a better payer relationship
  • Understanding and including the patients’ perspectives in designing clinical trials and clinical endpoint
  • Key principles that ensure access to treatment based on need
  • Patient-centeredness, patient advocacy
  • Challenges in the smooth transition of the new EU regulatory framework
  • New challenges for R&D and Market Access
  • Any updates addressing other requirements for various categories of devices
  • Key differences from Pharmaceutical regulation
  • Innovative approaches required to address the medicine access challenge
  • Lessons to be learned from best practices in the field of pricing and reimbursement of medicines
  • The value of list prices against the backdrop of external price referencing and managed entry agreements.
  • Innovative policy options that need to be developed, agreed upon and implemented.

COLLABORATION & LOOKING TO THE FUTURE

  • Key trends driving the increase in value communication
  • Target audiences who receive VC information
  • Types of VC tools used to achieve market access
  • Outsourcing of VC projects
  • Areas in need of improvement
  • Training needs in VC
  • Unlocking data from early access
  • Effective communications with internal and external stakeholders
  • Embracing the digital vision
  • Future trends and developments in the healthcare distribution
  • What is EMA-HTA Parallel Consultation?
  • Importance of seeking early regulatory, HTA, and joint consultation
  • Current trends in parallel advice: What has changed?
  • Risk and advantages of using parallel consultation at the EU or national level?
  • Successful strategies to maximise the benefit of parallel consultation
  • The importance of making MA the core of the company
  • Bridge between pre-launch strategy and post-launch
  • International Drug Price Indicator Guide WHO
  • Increasing collaboration between EU countries
  • Frontiers in Health Care
  • What will the future bring?
Scroll to Top